Literature DB >> 33444534

From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.

Ajay M Verma1, Anusha Patel2, Sreedhar Subramanian3, Philip J Smith3.   

Abstract

Entities:  

Year:  2021        PMID： 33444534     DOI： 10.1016/S2468-1253(20)30392-7

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


× No keyword cloud information.
  11 in total

Review 1.  Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.

Authors:  Rieke Alten; Yoorim An; Dong-Hyeon Kim; SangWook Yoon; Laurent Peyrin-Biroulet
Journal:  Clin Drug Investig       Date:  2022-06-03       Impact factor: 2.859

Review 2.  Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence.

Authors:  Florenzo Iannone; Fabrizio Conti; Alberto Cauli; Alberto Farina; Roberto Caporali
Journal:  J Inflamm Res       Date:  2022-06-01

Review 3.  Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.

Authors:  Simeng Lin; Louis Hs Lau; Neil Chanchlani; Nicholas A Kennedy; Siew C Ng
Journal:  Gut       Date:  2022-04-27       Impact factor: 31.793

Review 4.  Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.

Authors:  Stefan Schreiber; Shomron Ben-Horin; Rieke Alten; René Westhovens; Laurent Peyrin-Biroulet; Silvio Danese; Toshifumi Hibi; Ken Takeuchi; Fernando Magro; Yoorim An; Dong-Hyeon Kim; SangWook Yoon; Walter Reinisch
Journal:  Adv Ther       Date:  2022-01-06       Impact factor: 4.070

5.  Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic.

Authors:  Shahida Din; Daniel Gaya; Jochen Kammermeier; Christopher A Lamb; Jonathan Macdonald; Gordon Moran; Gareth Parkes; Richard Pollok; Shaji Sebastian; Jonathan Segal; Christian Selinger; Philip J Smith; Helen Steed; Ian D Arnott
Journal:  Frontline Gastroenterol       Date:  2021-04-21

Review 6.  How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions.

Authors:  Piotr Eder; Aleksandra Zielińska; Jacek Karczewski; Agnieszka Dobrowolska; Ryszard Słomski; Eliana B Souto
Journal:  J Nanobiotechnology       Date:  2021-10-29       Impact factor: 10.435

7.  Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.

Authors:  Jurij Hanzel; Laura H Bukkems; Krisztina B Gecse; Geert R D'Haens; Ron A A Mathôt
Journal:  Aliment Pharmacol Ther       Date:  2021-09-24       Impact factor: 9.524

8.  Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS].

Authors:  Esther Ventress; David Young; Sohail Rahmany; Clare Harris; Marion Bettey; Trevor Smith; Helen Moyses; Magdalena Lech; Markus Gwiggner; Richard Felwick; J R Fraser Cummings
Journal:  J Crohns Colitis       Date:  2022-07-14       Impact factor: 10.020

9.  Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.

Authors:  Philip J Smith; Lisa Critchley; Daniel Storey; Belle Gregg; June Stenson; Andrew Kneebone; Tracy Rimmer; Stevena Burke; Shamas Hussain; Wan Yi Teoh; Stephan Vazeille; Solange Serna; Alan Steel; Edmund Derbyshire; Paul Collins; Martyn Dibb; Paul Flanagan; Christopher Probert; Ajay M Verma; Sreedhar Subramanian
Journal:  J Crohns Colitis       Date:  2022-09-08       Impact factor: 10.020

10.  Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series.

Authors:  Sooraj Vijayan; Kyungmin Hwangbo; Nick Barkham
Journal:  Clin Case Rep       Date:  2022-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.